- Title
- A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
- Creators
- Joseph Clark - Loyola University ChicagoLawrence Flaherty - The Barbara Ann Karmanos Cancer InstituteMarc Ernstoff - University of Michigan–Ann ArborHenry Koon - University Hospitals of ClevelandMohammed Milhem - University of IowaGerald Militello - Hematology\Oncology ClinicSanjiv Agarwala - Natural Resources Institute FinlandBrendan Curti - Providence Portland Medical CenterLee Cranmer - University of ArizonaChristopher D Lao - University of Michigan–Ann ArborTheodore F Logan - Indiana University – Purdue University IndianapolisJose Lutzky - University of MiamiVenkatesh Rudrapatna - University of MinnesotaGregory Daniels - University of Michigan–Ann ArborBret Taback - Columbia UniversitySandra Aung - Prometheus BiosciencesJames Lowder - Prometheus BiosciencesDavid Lawson - Emory University
- Publication Details
- Journal for immunotherapy of cancer, Vol.2(Suppl 3), pp.P77-P77
- Publisher
- BioMed Central
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031785532502976
Journal article
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
Journal for immunotherapy of cancer, Vol.2(Suppl 3), pp.P77-P77
2014-11-06
Metrics
1 Record Views